Current small cell lung cancer treatment in China
Yuankai Shi, Puyuan Xing, Yun Fan, Xin Zhang, Chengping Hu, Caixia Wang, Xiaoqing Liu, Xiaoxia Chen, Jianying Zhou, Mengzhao Wang, Meina Wu, Baohui Han, Min Fan, Yuankai Shi, Puyuan Xing, Yun Fan, Xin Zhang, Chengping Hu, Caixia Wang, Xiaoqing Liu, Xiaoxia Chen, Jianying Zhou, Mengzhao Wang, Meina Wu, Baohui Han, Min Fan
Abstract
Background: The treatment status of small cell lung cancer (SCLC) in Mainland China has never been reported; therefore, this study is the first multicenter survey investigating the status of epidemiology and treatment options of SCLC in Mainland China.
Methods: Two questionnaires were designed to obtain information in 12 medical centers in five major Chinese cities. The hospital information questionnaire was designed to outline SCLC patients' characteristics and treatment preferences in each medical institution, and the patient information questionnaire collected detailed treatment information of 298 SCLC cases in these hospitals.
Results: SCLC represented 13.7% and 18.3% of all lung cancer patients in 2005 and 2010, respectively. Clinical management of SCLC follows mainstream clinical guidelines in general. The most widely applied first-line treatment mode for limited-stage patients was combined chemoradiotherapy (66.2%), while 77.0% of the extensive-stage patients received chemotherapy alone as initial treatment. Etoposide with cisplatin or carboplatin were the most accepted first-line chemotherapy regimens. The objective response rate was 58.3% after first-line chemotherapy and 23% of the patients who responded well to first-line treatment received prophylactic cranial irradiation. As for second-line chemotherapy, single regimen topotecan or a combined regimen containing topotecan were preferred (53.0%).
Conclusions: The treatment options indicated in our study are in accordance with the international clinical guidelines, which is valuable for the improvement of future guidelines, health care standard, and even the better distribution of health care resources in China.
Keywords: Chemotherapy; Chinese population; epidemiology; radiotherapy; small cell lung cancer.
Figures
References
- International Agency for Research on Cancer. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. [Cited 25 Oct 2014.] Available from URL: .
- Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26:48–58.
- Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366:1385–1396.
- National Comprehensive Cancer Network. 2013. NCCN Clinical Practice Guidelines in Oncology: small cell lung cancer. Version 1. [Cited 16 Dec 2014.] Available from URL: .
- Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;24(Suppl 6):vi99–vi105.
- Zhi XY, Wu YL, Bu H, et al. Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011) J Thorac Dis. 2012;4:677–688.
- Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–4544.
- Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, Moller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012;75:280–284.
- Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294–299.
- Yang GH, Ma JM, Liu N, Zhou LN. Smoking and passive smoking in Chinese, 2002. Zhonghua Liu Xing Bing Xue Za Zhi. 2005;26:77–83. (In Chinese.)
- Dan X, Yuankai S, Chen W. Tobacco in China. Lancet. 2014;383:2045–2046.
- Lüchtenborg M, Riaz SP, Lim E, et al. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009. Thorax. 2014;69:269–273.
Source: PubMed